Geneva Partners LLC raised its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 59.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 9,145 shares of the medical research company’s stock after acquiring an additional 3,400 shares during the quarter. Thermo Fisher Scientific makes up 2.4% of Geneva Partners LLC’s portfolio, making the stock its 16th biggest holding. Geneva Partners LLC’s holdings in Thermo Fisher Scientific were worth $2,047,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Advisors Asset Management Inc. grew its position in shares of Thermo Fisher Scientific by 11.7% in the second quarter. Advisors Asset Management Inc. now owns 93,813 shares of the medical research company’s stock valued at $19,432,000 after purchasing an additional 9,832 shares during the period. Neville Rodie & Shaw Inc. grew its position in shares of Thermo Fisher Scientific by 1.7% in the third quarter. Neville Rodie & Shaw Inc. now owns 114,536 shares of the medical research company’s stock valued at $27,956,000 after purchasing an additional 1,965 shares during the period. We Are One Seven LLC purchased a new stake in shares of Thermo Fisher Scientific in the third quarter valued at $285,000. BKD Wealth Advisors LLC grew its position in shares of Thermo Fisher Scientific by 118.9% in the third quarter. BKD Wealth Advisors LLC now owns 2,342 shares of the medical research company’s stock valued at $572,000 after purchasing an additional 1,272 shares during the period. Finally, Pennsylvania Trust Co grew its position in shares of Thermo Fisher Scientific by 28.7% in the third quarter. Pennsylvania Trust Co now owns 53,277 shares of the medical research company’s stock valued at $13,004,000 after purchasing an additional 11,870 shares during the period. 86.88% of the stock is owned by institutional investors.

In other Thermo Fisher Scientific news, CFO Stephen Williamson sold 9,500 shares of the business’s stock in a transaction dated Friday, December 7th. The stock was sold at an average price of $241.45, for a total transaction of $2,293,775.00. Following the completion of the sale, the chief financial officer now owns 44,124 shares of the company’s stock, valued at $10,653,739.80. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Tyler Jacks sold 4,772 shares of the business’s stock in a transaction dated Monday, November 19th. The shares were sold at an average price of $239.75, for a total value of $1,144,087.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 32,607 shares of company stock valued at $7,972,085. 0.49% of the stock is owned by company insiders.

TMO stock opened at $243.59 on Tuesday. Thermo Fisher Scientific Inc. has a 12-month low of $194.51 and a 12-month high of $253.91. The company has a quick ratio of 1.23, a current ratio of 1.71 and a debt-to-equity ratio of 0.64. The stock has a market cap of $98.00 billion, a price-to-earnings ratio of 21.91, a PEG ratio of 1.60 and a beta of 1.14.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, January 30th. The medical research company reported $3.25 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.19 by $0.06. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 12.06%. The firm had revenue of $6.51 billion during the quarter, compared to the consensus estimate of $6.26 billion. During the same quarter in the previous year, the business earned $2.79 earnings per share. The firm’s quarterly revenue was up 7.6% compared to the same quarter last year. On average, research analysts anticipate that Thermo Fisher Scientific Inc. will post 12.15 earnings per share for the current year.

The company also recently declared a quarterly dividend, which was paid on Tuesday, January 15th. Shareholders of record on Monday, December 17th were given a dividend of $0.17 per share. This represents a $0.68 dividend on an annualized basis and a yield of 0.28%. The ex-dividend date of this dividend was Friday, December 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 6.12%.

A number of equities research analysts have recently commented on the company. Zacks Investment Research raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $271.00 price objective for the company in a research report on Friday, December 7th. Cleveland Research downgraded Thermo Fisher Scientific from a “buy” rating to a “neutral” rating in a research report on Thursday, October 18th. Morgan Stanley lifted their price objective on Thermo Fisher Scientific from $254.00 to $260.00 and gave the company an “overweight” rating in a research report on Thursday, October 25th. BTIG Research lifted their price objective on Thermo Fisher Scientific to $290.00 and gave the company a “buy” rating in a research report on Thursday, January 31st. Finally, Robert W. Baird lifted their price objective on Thermo Fisher Scientific from $256.00 to $264.00 and gave the company an “outperform” rating in a research report on Thursday, October 25th. Three equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. Thermo Fisher Scientific has a consensus rating of “Buy” and an average target price of $275.10.

ILLEGAL ACTIVITY NOTICE: “Geneva Partners LLC Has $2.05 Million Stake in Thermo Fisher Scientific Inc. (TMO)” was originally published by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The legal version of this report can be accessed at https://www.dailypolitical.com/2019/02/05/geneva-partners-llc-has-2-05-million-stake-in-thermo-fisher-scientific-inc-tmo.html.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Featured Story: Diversification Important in Investing

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.